Samuel Zachary Goldhaber, M.D.
Co-Author
This page shows the publications co-authored by Samuel Goldhaber and Paul Ridker.
Connection Strength
0.867
-
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
Score: 0.197
-
D-dimer and duration of anticoagulation. N Engl J Med. 2007 Jan 25; 356(4):422-3; author reply 423.
Score: 0.087
-
Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006 Oct; 4(10):2199-203.
Score: 0.084
-
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Nov 27; 349(22):2164-7; author reply 2164-7.
Score: 0.070
-
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10; 348(15):1425-34.
Score: 0.066
-
G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001 Jan; 37(1):215-8.
Score: 0.057
-
Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997 Apr 01; 126(7):528-31.
Score: 0.044
-
Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995 Nov 15; 92(10):2800-2.
Score: 0.040
-
Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. Am J Cardiol. 1992 Jul 01; 70(1):10-3.
Score: 0.032
-
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation. 1992 May; 85(5):1822-7.
Score: 0.031
-
The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J. 1991 Dec; 122(6):1588-92.
Score: 0.030
-
Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation. 1991 Aug; 84(2):708-11.
Score: 0.030
-
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010 Jan; 8(1):95-100.
Score: 0.026
-
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med. 2007 Oct 16; 147(8):525-33.
Score: 0.023
-
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007 Sep 25; 116(13):1497-503.
Score: 0.023
-
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006 Jun; 4(6):1208-14.
Score: 0.021
-
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med. 1990 Dec; 89(6):772-6.
Score: 0.007
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.